On February 19, 2024 Crossfire Oncology reported that the Crossfire team will present 3 posters at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) annual meeting 2024 (Press release, Crossfire Oncology, FEB 19, 2024, View Source [SID1234643984]). We will highlight the latest data on our best-in-class macrocyclic BTK inhibitor CFON-026, our novel Degrader Antibody Conjugate (DAC) technology, and our proprietary EPriL platform, which sits at the heart of both CFON-026 and our DACs.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
On Monday April 8, we will present our clinical candidate CFON-026, a best-in-class non-covalent macrocyclic BTK inhibitor that has potent activity towards BTK wild-type and all its clinically relevant mutant variants. The macrocycle structure of CFON-026 ensures a unique covalent-like binding mode based on β-sheet complementation. This not only allows for targeting BTK wild-type and BTK[C481S], often acquired following treatment with covalent BTK inhibitors, but also BTK[T474I] which arises with high incidence following pirtobrutinib treatment. CFON-026 is currently in preclinical development and expected to enter the clinic H2 2025.
On Tuesday April 9, we will present our EPriL (Energetically Privileged Ligands) macrocycle platform and how its chemical versatility was used to create a library of kinase degraders. Applying a screening cascade, novel degraders were discovered with high kinase selectivity and excellent potency.
On Tuesday April 9, we will present the opportunities that our EPriL platform provides for the generation of DACs. EPriL-based degraders have intrinsic properties that make them extraordinarily suitable for conjugation to antibodies. This will overcome the physicochemical challenges observed with degraders and increase the therapeutic window, thus improving their clinical potential. Our internal conjugation and in vitro testing platform enable the rapid exploration of powerful new degrader-antibody combinations for the treatment of cancer.
CFON-026 is a potent non-covalent BTK inhibitor suitable for combination therapy with covalent BTK inhibitors for early eradication of resistance mutations
Experimental and Molecular Therapeutics, abstract no. 1960
Monday Apr 8, 2024 9:00 AM – 12:30 PM
Presenter: Jos de Man
EPriL: A platform for the rapid identification of degraders of inhibitor-resistant kinases
Experimental and Molecular Therapeutics, abstract no. 6044
Tuesday Apr 9, 2024 1:30 PM – 5:00 PM
Presenter: Michelle Muller
EPriL macrocycles as a platform for the rapid generation of effective kinase degrader antibody conjugates (DACs)
Experimental and Molecular Therapeutics, abstract no. 5814
Tuesday Apr 9, 2024 1:30 PM – 5:00 PM
Presenter: Joost Uitdehaag